Representational AI image
T’puram: Researchers at the BRIC–Rajiv Gandhi Centre for Biotechnology (RGCB) in Thiruvananthapuram have received a Rs 7 crore grant to develop an automated diagnostic device that could help detect cervical cancer at an early-stage using a blood sample, potentially reducing the need for invasive procedures. More than 1,000 proposals were received for the ANRF grant, of which 33 were selected, she said. The project is supported by MAHA MedTech Mission, launched by Anusandhan National Research Foundation (ANRF), Indian Council of Medical Research (ICMR) and Gates Foundation. You Can Also Check: Gold Rate in Kochi | Silver Rate in Kochi | Bank Holidays in Kochi | Public Holidays in Kochi Stay updated with the latest Kochi news.
RGCB director Beena Pillai said the centre was proud to have secured the grant. Project lead researcher Jackson James said the technology was being designed for use beyond specialised laboratory settings. Once developed and validated, the system would analyse a patient‘s blood sample automatically, he said. A member of the research team, Ani V Das, said the technology could potentially improve access to screening in areas with limited laboratory infrastructure.
RGCB is collaborating with Thiruvananthapuram-based start-up IndZita Biotech Private Ltd and Karkinos Healthcare Private Ltd, Barshi, Maharashtra, for the research. The proposed device will detect piRNA-based biomarkers in blood samples and analyse them using nanopore technology, a sensitive molecular detection platform. The aim is to develop a rapid, automated system that can operate with minimal specialised training. The technology has been patented, and laboratory-scale validation has been completed using cell cultures and mouse models. A pilot study involving human blood samples has also been completed at the laboratory level. An early-stage prototype is currently under development. The team, comprising James, Das and Mahendran K R, aims to develop a functional diagnostic platform. Download the TOI App.
Further clinical validation and regulatory approval will be required before the technology can be used for routine screening.